Santa Cruz Biotechnology
A biotechnology supplier specializing in antibodies, research reagents, laboratory products, and gene-editing tools.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
History
Santa Cruz Biotechnology was established in 1991 in Santa Cruz, California, by John Stephenson and Brenda Stephenson. The company initially focused on antibodies, supplying research institutions and other scientific users with tools for detecting and studying biological molecules. Its early identity was therefore closely tied to the research-antibody market rather than to the development of therapeutic medicines for patients. Over time, SCBT developed a wider catalog of research-use materials. The company added small-interfering RNA products in 2007 and short hairpin RNA products in 2009. These product families supported gene-silencing experiments, giving researchers methods for reducing the expression of selected genes. Laboratory supplies and labware were added in 2010, extending the business beyond biological reagents into the broader infrastructure used by laboratories. The company also expanded its biochemical range. By 2010, its historical product description stated that the biochemical catalog had grown from a few hundred items to more than 100,000 products. This expansion reflected a catalog-based commercial strategy: researchers could source antibodies, biochemical compounds, kits, and laboratory materials from one supplier rather than relying on a narrow specialist portfolio. In 2015, Santa Cruz Biotechnology entered the CRISPR research-product field. Its CRISPR offering was described as covering more than 37,000 mouse and human genes. The move connected the company to a rapidly developing area of molecular biology and broadened its relevance to genetics, functional genomics, cell biology, and biomedical research. The company's facilities have been distributed across the United States and abroad. Its headquarters are identified as Dallas, Texas, while additional US facilities are located in Paso Robles, California, and Sun Valley, Idaho. International locations have included Germany, Shanghai, and Canada. These locations supported the company's international supply and distribution activities. A major disruption to the company's history came from regulatory scrutiny concerning animal treatment. USDA inspectors reported evidence that led to three animal-welfare complaints involving the company's California facility. The allegations concerned compliance with the Animal Welfare Act. In May 2016, Santa Cruz Biotechnology settled with the USDA. The reported settlement required a $3.5 million payment and provided for revocation of the company's polyclonal-antibody dealer license beginning December 31, 2016. The fine was characterized in the available reference material as the largest in USDA history. The available reference material does not provide reliable information about later ownership, leadership, financial performance, or corporate activity. Accordingly, the company's current operating status and present executive structure remain unconfirmed in this dossier. Its documented historical identity is that of a large supplier of antibodies and a diversified provider of research reagents, gene-silencing products, CRISPR tools, laboratory supplies, and related biological products.
- 2016
USDA animal-welfare settlement
[1]SCBT settled allegations concerning Animal Welfare Act violations, with a reported $3.5 million payment and planned revocation of its polyclonal-antibody dealer license.
- 2015
CRISPR product range introduced
[1]The company introduced CRISPR-related products covering more than 37,000 mouse and human genes.
- 2010
Laboratory supplies introduced and biochemical catalog expanded
[1]SCBT added laboratory supplies and reported expanding its biochemical offering to more than 100,000 products.
- 2009
shRNA products added
[1]The company introduced short hairpin RNA products, extending its gene-regulation and gene-silencing portfolio.
- 2007
siRNA products added
[1]SCBT expanded beyond antibodies by adding small-interfering RNA products for gene-silencing research.
- 1991
Company founded in Santa Cruz, California
[1]John Stephenson and Brenda Stephenson founded Santa Cruz Biotechnology and began building a business focused on supplying antibodies to the research community.
Products and positioning
Broad catalog supplier of research-use biological products and laboratory reagents
Research reagents · 1991
Antibodies
Antibodies formed the company's original and most prominent product category. SCBT supplied antibodies used by research laboratories to detect, characterize, and investigate proteins and other biological targets in applications including molecular biology, cell biology, immunology, and biomedical research.
Biochemical reagents
Biochemicals
The biochemical line included a broad catalog of research compounds and reagents. The company reported a substantial expansion of this range, from several hundred items to more than 100,000 products by 2010, making biochemicals a major part of its catalog-supplier model.
Gene-silencing research tools · 2007
siRNA products
SCBT added small-interfering RNA products in 2007. These materials are used in laboratory experiments that reduce expression of selected genes and help researchers examine gene function and cellular pathways.
Gene-silencing research tools · 2009
shRNA products
Short hairpin RNA products were added in 2009. They extended the company's gene-silencing portfolio and provided researchers with another approach to studying the effects of targeted gene suppression.
Gene-editing research tools · 2015
CRISPR products
Introduced in 2015, SCBT's CRISPR-related products were described as covering more than 37,000 mouse and human genes. The range extended the company's catalog into gene-editing and functional-genomics research.
Laboratory equipment and supplies · 2010
Laboratory supplies and labware
SCBT added laboratory supplies and labware in 2010. These products complemented its biological reagents by serving routine laboratory handling, preparation, and experimental needs.
Controversies
2016
Animal Welfare Act allegations and USDA settlement
USDA inspections led to three animal-welfare complaints concerning alleged mistreatment at a Santa Cruz Biotechnology facility in California. In May 2016, the company settled with the USDA, reportedly paying $3.5 million and agreeing to revocation of its polyclonal-antibody dealer license effective December 31, 2016.
Brand decisions
2016
Settlement with the USDAOtherBackground
USDA complaints and inspections raised alleged violations of the Animal Welfare Act at a company facility in California.
Action taken
SCBT settled with the USDA, reportedly paid a $3.5 million fine, and agreed to revocation of its polyclonal-antibody dealer license effective December 31, 2016.
Aftermath
The settlement became the company's defining regulatory and reputational event in the available historical record.
USDA settlement payment. $3.5 million (May 2016 settlement)
2015
Entry into CRISPR research productsProduct launchBackground
CRISPR-based methods were becoming important tools in genetics and functional genomics.
Action taken
SCBT introduced CRISPR-related products covering more than 37,000 mouse and human genes.
Aftermath
The launch broadened the company’s positioning as a supplier of molecular-biology and gene-editing research tools.
2009
Expansion into shRNA productsProduct launchBackground
SCBT continued diversifying beyond antibodies into tools for experimental gene suppression.
Action taken
The company introduced short hairpin RNA products.
Aftermath
The product range gained another gene-silencing modality for research customers.
2007
Expansion into siRNA productsProduct launchBackground
The company was broadening its original antibody business into gene-regulation and molecular-biology tools.
Action taken
SCBT added small-interfering RNA products to its research catalog.
Aftermath
The move expanded the company's offering into gene-silencing research.
Recent events
- 2015
Santa Cruz Biotechnology expands into CRISPR research products[1]
Product launch · Product generation
SCBT introduced CRISPR-related products covering more than 37,000 mouse and human genes, extending its catalog into gene-editing research tools.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/santa-cruz-biotechnology · Editorial policy · How profiles are compiled